Drug companies 'not happy' that drug prices 'are going down,' Trump tweets » 10:0008/1308/13/20
JNJ, LLY, MRK, PFE, SNY, AZN, GSK, NVS, RHHBY, BMY
President Donald Trump…
President Donald Trump tweeted: "Drug companies, which are being forced by me to substantially reduce Drug Prices, are taking $millions in ads saying I want to increase Medicare Primiums. Wrong, just the opposite! These ads show DRUG PRICES ARE GOING DOWN, and they are not happy! False advertising!" Large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
Novocure announces Wilco Groenhuysen as COO, other leadership promotions » 08:3608/1308/13/20
Novocure (NVCR) announced…
Novocure (NVCR) announced an expansion of its executive leadership team, effective September 1. After eight years of service as CFO, Wilco Groenhuysen has been appointed to an expanded COO role responsible for the general and administrative management of the company. He will also assume responsibility for the strategic and operational leadership of Novocure's supply chain, warehousing and distribution, quality assurance and information technology operations. Groenhuysen is tasked to ensure organizational readiness in anticipation of the completion of four Phase 3 clinical trials over the next few years. Ashley Cordova has been promoted to CFO and will assume responsibility for the oversight of Novocure's global financial operations, including financial reporting, financial planning and analysis, treasury, tax, and investor relations. In her new role, Cordova will report directly to Asaf Danziger, Novocure's CEO. Cordova has played a role in leading multiple financial functions for Novocure with increasing responsibilities since she joined as director of global treasury in 2014. Prior to joining Novocure, Ms. Cordova served in various financial roles at Pfizer (PFE). Frank Leonard has been promoted to chief development officer, a newly created executive role with responsibility for engineering, product development, business development and the overall strategic and operational leadership of Novocure's innovation platforms. In his new role, Leonard will report directly to Danziger. Leonard joined Novocure in 2010 to help prepare the company for the commercial launch of Optune. In this role, he established Novocure's health policy and business development groups, and additionally led various finance functions. Prior to joining Novocure, Leonard was a venture capital investor focused on high-impact medical technologies.
Akcea Therapeutics' Waylivra new pricing and reimbursement approved in Germany » 07:1208/1308/13/20
Akcea Therapeutics announced that the German Association of Statutory Sick Funds has agreed upon new pricing and reimbursement of Waylivra as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome - FCS - and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. Waylivra has been commercially available in Germany since August 15, 2019. As part of reimbursement and market access protocol in Germany, Akcea was required to renegotiate the Waylivra launch price 12 months after first commercialization, which will go into effect on August 15. FCS is a debilitating genetic disease caused by impaired function of the enzyme lipoprotein lipase, which results in significant risk and disease burden. It is estimated that there are between 3,000 to 5,000 people living with FCS worldwide.
Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call » 11:4508/1208/12/20
PFE, MRK, ALPMY, PCVX, SNY
Large Cap & Biopharma…
Large Cap & Biopharma Analysts Chen & Kim, along with Dr. Arnold Lentnek, Medical Director at Infectious Disease Medical Practice of NY, debate which company will have the best-in-class next-generation pneumococcal conjugate vaccines franchise on an Analyst/Industry conference call to be held on August 19 at 1 pm.
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 11:4408/1208/12/20
PFE, MMA, AZN, LLY
Large Cap & Biopharma…
Large Cap & Biopharma Analysts Chen & Kim, along with Key Opinion Leader Dr. Robert Kruse, of Johns Hopkins School of Medicine, discuss Pfizer vs Moderna's COVID-19 vaccine, as well as other leading vaccines in development including AstraZeneca, Eli Lilly, Oxford, on an Analyst/Industry conference call to be held on August 18 at 1 pm.
Honeywell downgrade among today's top calls on Wall Street » 10:1308/1108/11/20
HON, ALNY, MELI, ESPR, MSI
Check out today's top…
Alnylam downgraded to Perform on valuation at Oppenheimer » 09:2108/1108/11/20
As previously reported,…
As previously reported, Oppenheimer analyst Leland Gershell downgraded Alnylam to Perform from Outperform with a price target of $156, down from $162. While the analyst believes the broad potential of the company's RNAi platform justifies high EV/revenue multiples relative to peers, he expects limited near-term upside pending catalysts that lie sometime away.
BridgeBio announces anticipated major milestones » 07:4708/1108/11/20
Major milestones anticipated over the next 18-24 months for BridgeBio's four core value drivers: Acoramidis - TTR stabilizer for ATTR: Remain on track to complete enrollment in the Phase 3 ATTRibute-CM study in ATTR cardiomyopathy in the first half of 2021, with topline data expected in the first half of 2022. Acoramidis is a potentially best in class TTR stabilizer for ATTR-CM, a large and growing disease affecting greater than400K patients globally, and one of the first drug candidates to arise from BridgeBio's drug engineering platform. Low-dose infigratinib - FGFR1-3 inhibitor for achondroplasia: Remain on track to report initial data from the ongoing Phase 2 dose ranging study by YE2021. Achondroplasia is the most common form of genetic short stature and one of the most commonly-known genetic diseases, with greater than55K cases in the US and EU. Low-dose infigratinib is the only known therapy in development for achondroplasia that targets the disease at its genetic source and the only orally administered product candidate in clinical stage development.Encaleret - CaSR antagonist for Autosomal Dominant Hypocalcemia Type 1: Remain on track to initiate the planned Phase 2 study in 2020, with potential proof-of-concept data available in 2021. If the development program is successful, encaleret would be the first approved therapy for ADH1, a condition caused by gain of function variants in the calcium-sensing receptor gene estimated to be carried by 12k individuals in the US. BBP-631 - AAV5 gene therapy candidate for congenital adrenal hyperplasia: IND-enabling studies for AAV gene therapy proceeding. Remain on track to initiate a first in human Phase 1/2 study and report initial data in 2021. CAH is one of the most prevalent genetic diseases thought to be addressable with AAV gene therapy, with greater than75K cases in the US and EU.
BridgeBio says 'adequately financed' through key readouts of core programs » 07:4508/1108/11/20
The company said,…
The company said, "BridgeBio remains on track with each of its four core value drivers - acoramidis for ATTR cardiomyopathy, low-dose infigratinib for achondroplasia, AAV5 gene therapy for congenital adrenal hyperplasia, and encaleret for autosomal dominant hypocalcemia type 1- and the company believes it is adequately financed through key readouts for each of these programs. Notably, BridgeBio dosed the first child in its Phase 2 clinical trial of infigratinib in achondroplasia in July."
BridgeBio reports Q2 EPS ($1.03), consensus (77c) » 07:4408/1108/11/20
"On a risk-adjusted…
"On a risk-adjusted basis we are in a great position to produce meaningful medicines for patients and meaningful returns to investors over the next 18 to 24 months. This is exemplified by our disease-modifying, first or best-in-class therapeutic candidates for ATTR, achondroplasia, ADH1, and CAH. We intend to deliver on this goal by expanding our industry-leading target identification and research engine and global clinical development infrastructure, and look forward to delivering our medicines, once approved, to patients through our growing commercial organization," said BridgeBio CEO and founder Neil Kumar, Ph.D.